Critical appraisal of ranibizumab in the treatment of diabetic macular edema

Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The forma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Stewart MW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2026073f3089400d93fa4e116c21646f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2026073f3089400d93fa4e116c21646f
record_format	dspace
spelling	oai:doaj.org-article:2026073f3089400d93fa4e116c21646f2021-12-02T02:10:39ZCritical appraisal of ranibizumab in the treatment of diabetic macular edema1177-54671177-5483https://doaj.org/article/2026073f3089400d93fa4e116c21646f2013-06-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-ranibizumab-in-the-treatment-of-diabetic-macular-a13436https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The formation of DME depends on the action of several growth factors and inflammatory mediators, but vascular endothelial growth factor (VEGF) appears to be critical for breaking down the blood-retinal barrier and promoting the accumulation of macular edema. Laser photocoagulation has been the standard-of-care for three decades, and although it stabilizes vision, significant gains in visual acuity after treatment are unusual. Several VEGF inhibitors (pegaptanib, aflibercept, and ranibizumab) have been initially developed and tested for the treatment of age-related macular degeneration and subsequently for DME. In Phase I, II, and III trials for DME, ranibizumab has been shown to be superior to macular laser photocoagulation and intraocular triamcinolone acetonide injections for improving visual acuity and drying the macula. As a result, ranibizumab is the only anti-VEGF drug that has been approved by the United States Food and Drug Administration for the treatment of DME. Most experts now consider intravitreal anti-VEGF therapy to be standard-of-care for DME involving the fovea.Keywords: aflibercept, bevacizumab, diabetic macular edema, diabetic retinopathy, ranibizumab, vascular endothelial growth factorStewart MWDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1257-1267 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Stewart MW Critical appraisal of ranibizumab in the treatment of diabetic macular edema
description	Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The formation of DME depends on the action of several growth factors and inflammatory mediators, but vascular endothelial growth factor (VEGF) appears to be critical for breaking down the blood-retinal barrier and promoting the accumulation of macular edema. Laser photocoagulation has been the standard-of-care for three decades, and although it stabilizes vision, significant gains in visual acuity after treatment are unusual. Several VEGF inhibitors (pegaptanib, aflibercept, and ranibizumab) have been initially developed and tested for the treatment of age-related macular degeneration and subsequently for DME. In Phase I, II, and III trials for DME, ranibizumab has been shown to be superior to macular laser photocoagulation and intraocular triamcinolone acetonide injections for improving visual acuity and drying the macula. As a result, ranibizumab is the only anti-VEGF drug that has been approved by the United States Food and Drug Administration for the treatment of DME. Most experts now consider intravitreal anti-VEGF therapy to be standard-of-care for DME involving the fovea.Keywords: aflibercept, bevacizumab, diabetic macular edema, diabetic retinopathy, ranibizumab, vascular endothelial growth factor
format	article
author	Stewart MW
author_facet	Stewart MW
author_sort	Stewart MW
title	Critical appraisal of ranibizumab in the treatment of diabetic macular edema
title_short	Critical appraisal of ranibizumab in the treatment of diabetic macular edema
title_full	Critical appraisal of ranibizumab in the treatment of diabetic macular edema
title_fullStr	Critical appraisal of ranibizumab in the treatment of diabetic macular edema
title_full_unstemmed	Critical appraisal of ranibizumab in the treatment of diabetic macular edema
title_sort	critical appraisal of ranibizumab in the treatment of diabetic macular edema
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/2026073f3089400d93fa4e116c21646f
work_keys_str_mv	AT stewartmw criticalappraisalofranibizumabinthetreatmentofdiabeticmacularedema
_version_	1718402636352323584

Critical appraisal of ranibizumab in the treatment of diabetic macular edema

Ejemplares similares